Posted from: Sunday, December 11, 2016 - 04:34 PM - Present

New Generic for Concerta

Oct. 21, 2016 - The US FDA approved an AB-rated (therapeutically equivalent) generic for Concerta (methylphenidate). Its AB rating means that the new generic is interchangeable with Concerta, which is manufactured by Janssen.  This approval comes shortly after the FDA announced that it was initiating actions to revoke approval for two extended-release methylphenidate products that are rated BX (presumed therapeutically inequivalent) to Concerta. Mylan, the manufacturer of the new generic for Concerta has not yet released any launch or pricing details. Actavis distributes an authorized generic, which will remain on the market.

 

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

Last Updated Sunday, May 21, 2017 - 04:07 AM.